Medicines Discovery Catapult Limited
Private, limited by guarantee, no share capital · Macclesfield
ActiveUnited KingdomIncorporated 2015Private, limited by guarantee, no share capital
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
No processed account filings
No processed accounts are available in our records.
Registered details
09928547- Status
- Active
- Type
- Private, limited by guarantee, no share capital
- Incorporated
- 2015-12-23
- Jurisdiction
- —
- Registered office
- BLOCK 35G, MERESIDE, ALDERLEY PARK, MACCLESFIELD, CHESHIRE, SK10 4ZF, ENGLAND
Classification
1 SIC codes73103
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
37 matched grantsNascent Therapeutics LtdLead
Innovate UK · Centres · 2026-03-01 – 2026-03-31
£500,000
awarded
Enhanced assays for low dose, high potency RNA-LNP medicinesInnovate UK · Grant for R&D · 2026-02-01 – 2026-07-31 · with 1 other participant£0awarded
Enhanced assays for low dose, high potency RNA-LNP medicines
Innovate UK · Grant for R&D · 2026-02-01 – 2026-07-31 · with 1 other participant
£0
awarded
Medicines Discovery Catapult Limited£0
Flip Therapeutics LimitedLead
Innovate UK · Centres · 2026-01-01 – 2026-03-31
£500,000
awarded
Smart Personalised Healthcare: Evaluation, Response and Engagement (SPHERE)Innovate UK · Centres · 2025-10-01 – 2026-03-31 · with 3 other participants£208,329awarded
Smart Personalised Healthcare: Evaluation, Response and Engagement (SPHERE)
Innovate UK · Centres · 2025-10-01 – 2026-03-31 · with 3 other participants
£208,329
awarded
Medicines Discovery Catapult Limited£208,329
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development CompanyLiveInnovate UK · Collaborative R&D · 2025-06-01 – 2027-03-31 · with 1 other participant£111,063awarded
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development CompanyLive
Innovate UK · Collaborative R&D · 2025-06-01 – 2027-03-31 · with 1 other participant
£111,063
awarded
Medicines Discovery Catapult Limited£111,063
A collaborative approach to establish the metabolites and safety of KT-001, advancing the commercialisation of an innovative new treatment for melanoma.LiveInnovate UK · Collaborative R&D · 2025-06-01 – 2026-11-30 · with 1 other participant£112,445awarded
A collaborative approach to establish the metabolites and safety of KT-001, advancing the commercialisation of an innovative new treatment for melanoma.Live
Innovate UK · Collaborative R&D · 2025-06-01 – 2026-11-30 · with 1 other participant
£112,445
awarded
Medicines Discovery Catapult Limited£112,445
Harvesting the UK's Radionuclide Assets for Medical ApplicationsInnovate UK · Feasibility Studies · 2025-01-01 – 2025-06-30 · with 1 other participant£14,938awarded
Harvesting the UK's Radionuclide Assets for Medical Applications
Innovate UK · Feasibility Studies · 2025-01-01 – 2025-06-30 · with 1 other participant
£14,938
awarded
Medicines Discovery Catapult Limited£14,938
Catapult Investment Pilot 1Lead
Innovate UK · Centres · 2024-04-01 – 2025-05-31
£300,000
awarded
Psychiatry Consortium: Accelerating Medicines Discovery for Mental HealthLead
Innovate UK · Department for Science, Innovation & Technology · 2024-03-01 – 2024-10-31
£96,429
awarded
Neurodegeneration Initiative Initiation StageLead
Innovate UK · Collaborative R&D · 2023-12-01 – 2025-08-31
£761,174
awarded
Product optimisation of a novel new melanoma therapy using advanced microscopy and biomarkers to enhance the commercialisation of this technology.Innovate UK · Collaborative R&D · 2023-11-01 – 2025-05-31 · with 1 other participant£147,397awarded
Product optimisation of a novel new melanoma therapy using advanced microscopy and biomarkers to enhance the commercialisation of this technology.
Innovate UK · Collaborative R&D · 2023-11-01 – 2025-05-31 · with 1 other participant
£147,397
awarded
Medicines Discovery Catapult Limited£147,397
FER (H&L) AMR PACE (A-0438) consortium agreementLeadLive
Innovate UK · Collaborative R&D · 2023-09-01 – 2028-10-31
£9,402,620
awarded
FER (H&L) AMR PACE (A-0438) grant funding agreementLeadLive
Innovate UK · Collaborative R&D · 2023-09-01 – 2028-10-31
£6,597,379
awarded
Medicine Discovery Catapult Core Delivery ProgrammeLeadLive
Innovate UK · Centres · 2023-04-01 – 2028-03-31
£55,584,939
awarded
Building a UK IntraCellular Drug Delivery Centre (ICDDC)ISCF · Centres · 2023-01-01 – 2026-03-30 · with 4 other participants£10,000,000whole project
Building a UK IntraCellular Drug Delivery Centre (ICDDC)
ISCF · Centres · 2023-01-01 – 2026-03-30 · with 4 other participants
£10,000,000
whole project
Centre For Process Innovation LimitedleadImperial College LondonMedicines Discovery Catapult LimitedUniversity Of LiverpoolUniversity Of Strathclyde
Building a UK IntraCellular Drug Delivery Centre (ICDDC)Innovate UK · Centres · 2023-01-01 – 2026-03-31 · with 4 other participants£1,175,650awarded
Building a UK IntraCellular Drug Delivery Centre (ICDDC)
Innovate UK · Centres · 2023-01-01 – 2026-03-31 · with 4 other participants
£1,175,650
awarded
University of Strathclyde£1,340,293
Medicines Discovery Catapult Limited£1,175,650
An automated optical device that uses direct visualisation of single molecules for routine screening of cancer biomarkers.Innovate UK · Collaborative R&D · 2022-12-01 – 2024-10-31 · with 1 other participant£249,768awarded
An automated optical device that uses direct visualisation of single molecules for routine screening of cancer biomarkers.
Innovate UK · Collaborative R&D · 2022-12-01 – 2024-10-31 · with 1 other participant
£249,768
awarded
Medicines Discovery Catapult Limited£249,768
Pre-clinical Development of novel ‘self’-antibodies for disease modification in Huntington’s DiseaseInnovate UK · Collaborative R&D · 2022-12-01 – 2025-02-28 · with 1 other participant£371,510awarded
Pre-clinical Development of novel ‘self’-antibodies for disease modification in Huntington’s Disease
Innovate UK · Collaborative R&D · 2022-12-01 – 2025-02-28 · with 1 other participant
£371,510
awarded
Medicines Discovery Catapult Limited£371,510
Treatment of resected brain tumour beds using nanoparticle enhanced radiotherapyInnovate UK · Collaborative R&D · 2022-10-01 – 2024-03-31 · with 1 other participant£160,488awarded
Treatment of resected brain tumour beds using nanoparticle enhanced radiotherapy
Innovate UK · Collaborative R&D · 2022-10-01 – 2024-03-31 · with 1 other participant
£160,488
awarded
Medicines Discovery Catapult Limited£160,488
SUMMIT: SiRNAs Utilising MergoⓇ delivery for post-Myocardial Infarction TreatmentInnovate UK · Collaborative R&D · 2022-04-01 – 2024-03-31 · with 2 other participants£162,910awarded
SUMMIT: SiRNAs Utilising MergoⓇ delivery for post-Myocardial Infarction Treatment
Innovate UK · Collaborative R&D · 2022-04-01 – 2024-03-31 · with 2 other participants
£162,910
awarded
Medicines Discovery Catapult Limited£162,910
Quantum Enhanced Computing Platform for Pharmaceutical R&D - QuPharmaISCF · Collaborative R&D · 2022-03-01 – 2025-03-30 · with 6 other participants£5,069,355whole project
Quantum Enhanced Computing Platform for Pharmaceutical R&D - QuPharma
ISCF · Collaborative R&D · 2022-03-01 – 2025-03-30 · with 6 other participants
£5,069,355
whole project
Seeqc UK LimitedleadMedicines Discovery Catapult LimitedMerckOxford NanoScience LimitedRiverlane LtdStfc - LaboratoriesUniversity Of Oxford
Quantum Enhanced Computing Platform for Pharmaceutical R&D - QuPharmaInnovate UK · Collaborative R&D · 2022-03-01 – 2025-03-31 · with 6 other participants£243,588awarded
Quantum Enhanced Computing Platform for Pharmaceutical R&D - QuPharma
Innovate UK · Collaborative R&D · 2022-03-01 – 2025-03-31 · with 6 other participants
£243,588
awarded
STFC - Laboratories£1,003,287
Medicines Discovery Catapult Limited£243,588
University of Oxford£158,641
A novel automated optical device that rapidly screens large numbers of patient samples for past and present COVID-19 infectionInnovate UK · Collaborative R&D · 2021-08-01 – 2023-03-31 · with 2 other participants£246,451awarded
A novel automated optical device that rapidly screens large numbers of patient samples for past and present COVID-19 infection
Innovate UK · Collaborative R&D · 2021-08-01 – 2023-03-31 · with 2 other participants
£246,451
awarded
University of Cambridge£284,035
Medicines Discovery Catapult Limited£246,451
Novel protective 'self'-antibodies for disease modification in Huntington’s DiseaseInnovate UK · Collaborative R&D · 2021-03-01 – 2022-10-31 · with 1 other participant£149,446awarded
Novel protective 'self'-antibodies for disease modification in Huntington’s Disease
Innovate UK · Collaborative R&D · 2021-03-01 – 2022-10-31 · with 1 other participant
£149,446
awarded
Medicines Discovery Catapult Limited£149,446
Intratumoral injection of nanoparticles for cancer treatment - translation to clinical practiceInnovate UK · Study · 2020-12-01 – 2021-11-30 · with 2 other participants£74,620awarded
Intratumoral injection of nanoparticles for cancer treatment - translation to clinical practice
Innovate UK · Study · 2020-12-01 – 2021-11-30 · with 2 other participants
£74,620
awarded
Medicines Discovery Catapult Limited£74,620
TARGET: RNA nanotechnology delivery platform for gene therapies, towards commercialization in cancerInnovate UK · Study · 2020-11-01 – 2022-04-30 · with 1 other participant£142,543awarded
TARGET: RNA nanotechnology delivery platform for gene therapies, towards commercialization in cancer
Innovate UK · Study · 2020-11-01 – 2022-04-30 · with 1 other participant
£142,543
awarded
Medicines Discovery Catapult Limited£142,543
ONI-CoV2RNA: A single step imaging-based assay for direct detection of SARS-CoV-2 RNAInnovate UK · Collaborative R&D · 2020-10-01 – 2021-12-31 · with 2 other participants£30,616awarded
ONI-CoV2RNA: A single step imaging-based assay for direct detection of SARS-CoV-2 RNA
Innovate UK · Collaborative R&D · 2020-10-01 – 2021-12-31 · with 2 other participants
£30,616
awarded
Medicines Discovery Catapult Limited£30,616
IMmunity Profiling of pAtients with Covid-19 for Therapy and Triage (IMPACTT)Innovate UK · Collaborative R&D · 2020-10-01 – 2022-03-31 · with 1 other participant£541,356awarded
IMmunity Profiling of pAtients with Covid-19 for Therapy and Triage (IMPACTT)
Innovate UK · Collaborative R&D · 2020-10-01 – 2022-03-31 · with 1 other participant
£541,356
awarded
Medicines Discovery Catapult Limited£541,356
Enabling ConditionsInnovate UK · Centres · 2020-08-01 – 2021-03-31 · with 7 other participants£38,811awarded
Enabling Conditions
Innovate UK · Centres · 2020-08-01 – 2021-03-31 · with 7 other participants
£38,811
awarded
Medicines Discovery Catapult Limited£38,811
Pre-Clinical Validation and Translation of a Novel Anti-FibroticInnovate UK · Collaborative R&D · 2019-10-01 – 2021-01-31 · with 1 other participant£338,039awarded
Pre-Clinical Validation and Translation of a Novel Anti-Fibrotic
Innovate UK · Collaborative R&D · 2019-10-01 – 2021-01-31 · with 1 other participant
£338,039
awarded
Medicines Discovery Catapult Limited£338,039
Development of First-In Class Small Molecule Preclinical Candidate Anticoagulant Targeting Activated Factor XII with Minimal Risk of BleedingInnovate UK · Collaborative R&D · 2019-09-01 – 2021-05-31 · with 2 other participants£174,753awarded
Development of First-In Class Small Molecule Preclinical Candidate Anticoagulant Targeting Activated Factor XII with Minimal Risk of Bleeding
Innovate UK · Collaborative R&D · 2019-09-01 – 2021-05-31 · with 2 other participants
£174,753
awarded
Chief AI - Global provision of AI As A ServiceInnovate UK · Collaborative R&D · 2019-05-01 – 2021-04-30 · with 1 other participant£139,232awarded
Chief AI - Global provision of AI As A Service
Innovate UK · Collaborative R&D · 2019-05-01 – 2021-04-30 · with 1 other participant
£139,232
awarded
Medicines Discovery Catapult Limited£139,232
A Next-Generation Platform for Novel Drug Discovery Using Deep Learning of ADMET Properties.Innovate UK · Collaborative R&D · 2018-09-01 – 2020-08-31 · with 2 other participants£303,139awarded
A Next-Generation Platform for Novel Drug Discovery Using Deep Learning of ADMET Properties.
Innovate UK · Collaborative R&D · 2018-09-01 – 2020-08-31 · with 2 other participants
£303,139
awarded
Medicines Discovery Catapult Limited£303,139
Medicine Discovery Catapult Core Delivery ProgrammeLead
Innovate UK · Centres · 2018-04-01 – 2023-08-31
£62,466,655
awarded
Interim - Medicines Discovery Catapult Core Delivery Programme
Innovate UK · Centres · 2016-04-01 – 2019-03-31
£1,951,000
awarded
Interim - Medicines Discovery Catapult Core Delivery ProgrammeLead
Innovate UK · Centres · 2016-04-01 – 2019-03-31
£20,225,222
awarded
ORAC AI Enabled Translational Science PlatformInnovate UK · Collaborative R&D · with 1 other participant
ORAC AI Enabled Translational Science Platform
Innovate UK · Collaborative R&D · with 1 other participant
Medicines Discovery Catapult Limited—